evidence for oncolytic virotherapy: where have we got to and where are we going?
Clicks: 236
ID: 177548
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
236 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #168 of 245 articles by views in International journal of pharmaceutics
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.
| Reference Key |
turnbull2015virusesevidence
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Samantha Turnbull;Emma J. West;Karen J. Scott;Elizabeth Appleton;Alan Melcher;Christy Ralph |
| Journal | International journal of pharmaceutics |
| Year | 2015 |
| DOI |
10.3390/v7122938
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.